

	Month (%)	Quarter (%)	FYTD (%)	1 Year (%)	2 Years (% p.a.)	3 Years (% p.a.)	5 Years (% p.a.)	7 Years (% p.a.)	Since Inception [^] (% p.a.)	Since Inception Cumulative [^] (%)
Perennial Better Future Trust (Net)	+0.9	+5.8	+5.6	+4.0	+3.2	+3.1	+4.3	+5.3	+6.2	+57.8
S&P/ASX Small Ordinaries Accumulation Index	+8.4	+12.4	+11.5	+23.4	+15.7	+9.8	+7.9	+6.0	+6.5	+61.0
Value Added	-7.5	-6.6	-5.9	-19.4	-12.5	-6.7	-3.6	-0.7	-0.3	-3.2

[^]Since inception: 1 February 2018. Past performance is not a reliable indicator of future performance.

Overview

The benchmark Small Ordinaries Accumulation Index continued to rally and was up an exceptionally strong 8.4% in August. Consumer discretionary and resources stocks performed strongly as reporting season was generally better than feared. The portfolio was up 0.9%, underperforming by 7.5% as the resilient growth stocks in the portfolio failed to keep up with the strong rally despite a generally solid reporting season, with healthcare stocks, in particular, underperforming.

Positive relative contributors this month included IDP Education (+57.9%), 4D Medical (+137.5%) and Charter Hall (+16.0%).

Gold stocks were a 2.6% drag to relative performance during the month. The three major negative relative contributors during August were Telix Pharmaceuticals (-30.6%), Meridian Energy (-5.1%) and Immutep (-13.0%).

Similar themes have played out in the underperformance of the portfolio over the 12 months to 31 August where the index has been up 23.4%. Gold stocks have been a 7.2% performance drag over the year. While we have had some company specific weakness including IDP Education (-64.7%) and Genetic Signatures (-64.0%), our relatively defensive positioning in resilient growth stocks which have failed to keep up with the market has been a significant contributor to the portfolio lagging the strong market which has preferred more cyclical exposures despite increasing global macroeconomic headwinds.

Better Future Highlight

During the month portfolio holding Cochlear announced the release of its "Nexa" next generation cochlear implant.

The Nexa is a "smart" device which has spent the last 20 years in development. The smart device allows for the easy upgrading of the firmware to improve functionality as new features are developed.

Importantly for surgeons, the Nexa device is designed to allow better placement of the device when it is implanted to improve the likelihood of optimal performance. It also allows the patients required processor settings to be transferred from one device to another, for instance if the processor needs to be replaced. These new features improve outcomes for both patient's and clinicians.

In FY25 Cochlear sold almost 54,000 cochlear implants and invested \$292m in research and development.

Better Future Stats



The **portfolio is 88.6% less carbon intensive compared to the ASX300** and 87.2% less carbon intensive compared to the ASX Small Ords[^]



8 female Directors were appointed to the board across 8 portfolio companies in 2024, typically following engagement, totalling **81 female Directors since inception** as at 31 December 2024

Perennial Better Future Trust

The aim of the Trust is to grow the value of your investment over the long term by investing in companies predominantly outside the S&P/ASX Top 50 Index that conduct business taking into account environmental, social and governance ("ESG") considerations and/or businesses that are making a positive contribution to creating a better future. The Trust seeks to provide a total return (after fees) that exceeds the S&P/ASX Small Ordinaries Accumulation Index measured on a rolling three-year basis.

Portfolio Manager

Damian Cottier

APIR Code

WPC5600AU

Distribution Frequency

Annually (if any)

Minimum Initial Investment

\$25,000

Trust Inception Date

1 February 2018

Fees

1.20% p.a. + Performance fee

Growth of \$100,000 Since Inception



As at 31 August 2025. Performance shown net of fees with distributions reinvested. Does not take into account any taxes payable by an investor. Past performance is not a reliable indication of future performance.



111 dedicated ESG engagements in 2024 with management and boards about material risks and opportunities **across 34 portfolio companies**



33% of portfolio companies have a Reconciliation Action Plan, compared to 21% of the ASX300 and 12% of the ASX Small Ords as at 31 December 2024

Trust Review

The benchmark Small Ordinaries Accumulation Index continued to rally and was up an exceptionally strong 8.4% in August. Consumer discretionary and resources stocks performed strongly as reporting season was generally better than feared. The portfolio was up 0.9%, underperforming by 7.5% as the resilient growth stocks in the portfolio failed to keep up with the strong rally despite a generally solid reporting season, with healthcare stocks, in particular, underperforming.

Positive relative contributors this month included IDP Education (+57.9%), 4D Medical (+137.5%) and Charter Hall (+16.0%).

Gold stocks were a 2.6% drag to relative performance during the month. The three major negative relative contributors during August were Telix Pharmaceuticals (-30.6%), Meridian Energy (-5.1%) and Immutep (-13.0%).

Similar themes have played out in the underperformance of the portfolio over the 12 months to 31 August where the index has been up 23.4%. Gold stocks have been a 7.2% performance drag over the year. While we have had some company specific weakness including IDP Education (-64.7%) and Genetic Signatures (-64.0%), our relatively defensive positioning in resilient growth stocks which have failed to keep up with the market has been a significant contributor to the portfolio lagging the strong market which has preferred more cyclical exposures despite increasing global macroeconomic headwinds.

IDP Education delivered a better than feared result and outlook statement. While conditions remain challenging in a number of markets, especially Canada, the company expects to be in a position to grow earnings in FY26 and is well positioned if the market rebounds.

4D Medical announced that it had secured a strategic investment from Pro Medicus Ltd ahead of US Food and Drug Administration ("FDA") approval of the company's CT:VQ lung imaging product. Subsequent to month end the company announced that it had received FDA approval. The CT:VQ product delivers comprehensive lung function assessment without radioactive exposure or contrast agents with a key use case being to detect blood clots in lungs. The relative ease of the imaging process compared to existing procedures is of benefit to patients, doctors and hospitals.

Telix Pharmaceuticals delivered a weaker than expected result and also announced that the FDA had, in effect, delayed approval of the company's kidney imaging product as the FDA required more information in relation to the manufacturing process. Importantly, the FDA concerns did not relate to efficacy of the product.

Meridian Energy delivered a weak FY25 result due to difficult hydrology conditions on the South Island of New Zealand during the year. There was no material negative news in relation to Immutep during the month.

During reporting season, many of our resilient growth holdings such as NIB Holdings (+3.6%), Arena REIT (+10.1%), Smartgroup (+14.3%) and Chorus (+10.8%) delivered generally positive results and outlook statements. While the EQT Holdings (-9.2%) result was inline, the company was impacted by the WA Ombudsman Report in relation to the company's conduct in relation to the Noongar Charitable Trust and ASIC commencing civil proceedings in relation to the company's involvement in the Shield Master Fund matter. During the month we engaged with the company in relation to these allegations and the company's governance processes.

At month end, the portfolio held 42 stocks and cash of 9.9%. The weighted average Perennial-derived Environmental, Social, Governance and Engagement ("ESGE") Score of the Trust was 7.3 which is 28% higher than the benchmark ESGE Score of 5.7.


ESG Activity

ESG activity during the month included:

- The Better Future Team engaged with Treasury on Sustainable Investment product labelling consultation and submitted a response for Treasury.
- Participated in an IAST APAC roundtable on modern slavery risk in the energy transition.
- Met with CQE and ARF and discussed child safety governance in childcare, modern slavery risk in solar panel supply chains and physical climate risk disclosures.
- Met with GEM and discussed how the company is working on strengthening child safety governance.



Portfolio Manager:
Damian Cottier



Senior ESG Analyst
Aoife McCarthy

Invest Online Now



CERTIFIED BY RIAA



SUSTAINABLE PLUS
— CERTIFIED BY RIAA —



Signatory of:



The Perennial Better Future Trust has been certified by the Responsible Investment Association Australasia according to the strict operational and disclosure practices required under the Responsible Investment Certification Program. See <http://www.responsibleinvestments.com.au/> for details¹.

1. The Responsible Investment Certification Program does not constitute financial product advice. Neither the Certification Symbol nor RIAA recommends to any person that any financial product is a suitable investment or that returns are guaranteed. Appropriate professional advice should be sought prior to making an investment decision. RIAA does not hold an Australian Financial Services Licence.

Top 5 Active Positions	Trust (%)	Index (%)
Meridian Energy	5.8%	0.0%
NIB Holdings	5.6%	1.2%
AUB Group	4.9%	1.3%
Chorus	4.9%	1.3%
PEXA	4.8%	0.7%

*Based on Perennial Value Management Forecasts. While due care has been used in the preparation of forecasts information, actual outcomes may vary in a materially positive or negative manner.

Contact us



Level 27, 88 Phillip Street
Sydney NSW 2000



1300 730 032



invest@perennial.net.au



www.perennial.net.au

Issued by Perennial Value Management Limited (ABN 22 090 879 904, AFSL No. 247293) as the Investment Manager. The Responsible Entity is Perennial Investment Management Limited (ABN 13 108 747 637, AFSL No. 275101). Perennial Partners Limited (ABN 90 612 829 160) is a Corporate Authorised Representative (1293138) of Perennial Value Management Limited. Both the Investment Manager and Responsible Entity form part of Perennial Partners. This promotional statement is provided for information purposes only. Accordingly, reliance should not be placed on this promotional statement as the basis for making an investment, financial or other decision. This promotional statement does not take into account your investment objectives, particular needs or financial situation and is not intended to constitute advertising or advice of any kind and you should not construe the contents of promotional statement as legal, tax, investment or other advice. This promotional statement does not constitute an offer or inducement to engage in an investment activity nor does it form part of any offer documentation, offer or invitation to purchase, sell or subscribe for interests in any type of investment product or service. You should read and consider any relevant offer documentation applicable to any investment product or service and consider obtaining professional investment advice tailored to your specific circumstances before making any investment decision. While every effort has been made to ensure the information in this promotional statement is accurate, its accuracy, reliability or completeness is not guaranteed. Past performance is not a reliable indicator of future performance. Gross performance does not include any applicable management fees or expenses. Net performance is based on redemption price for the period and assumes that all distributions are reinvested. Fees indicated reflect the maximum applicable. Contractual arrangements, including any applicable management fee, may be negotiated with certain large investors. Investments in the Trusts must be accompanied by an application form. The current relevant product disclosure statements, additional information booklet, application forms and target market determination can be found on Perennials website www.perennial.net.au. Use of the information on our website is governed by Australian law and is subject to the terms of use. No distribution of this material will be made in any jurisdiction where such distribution is not authorised or is unlawful. The Certification Symbol is issued by the Responsible Investment Association Australasia (RIAA) ACN (641 046 666), AFSL (554110) and signifies that a product or service offers an investment style that takes into account environmental, social, governance or ethical considerations and that the Perennial Better Future Trust adheres to the operational and disclosure practices required under the Responsible Investment Certification Program for the category of Product. The classification signifies the degree to which sustainability is a consideration and binding investment criteria. The Perennial Better Future Trust is assessed against RIAA's Responsible Investment Standard and Assessment Note-Sustainability Classifications. There may be material differences between the definition and methodology of RIAA's classification system and the way the terms 'Responsible/Sustainable/Sustainable Plus' are used by the product in its own disclosures. For detailed information about RIAA, the Symbol and Perennial Better Future Trust's methodology, performance, stock holdings, remuneration and details about other responsible investment products certified by RIAA, refer to www.responsibleinvestments.com.au and our Financial Services Guide.